AMR Labs SA is pleased to announce the acquisition of the Biostarks brand and core assets, marking the start of a new chapter for one of Europe’s most ambitious at-home biomarker testing platforms.
This transaction enables AMR Labs SA to relaunch Biostarks with a strengthened operational foundation, a clearer scientific roadmap, and a product experience designed for scale across both consumer and professional channels. Our objective is straightforward: make biomarker testing more accessible, more actionable, and more clinically robust—without compromising on quality, compliance, or user trust.
A reboot with continuity—and a sharper execution standard
Biostarks has always been built around a compelling idea: bring high-quality biomarker insights to people where they are, through a frictionless at-home experience. What changes today is the operational and technical readiness behind that promise.
AMR Labs SA has acquired the brand and key assets to ensure continuity for the community and partners that believed in the vision—while rebuilding the platform with a higher bar on laboratory rigor, reliability, and scalability. This is not a cosmetic rebrand; it is a re-foundation designed to support long-term growth.
Expanding the value proposition: beyond “routine labs”
The at-home testing market has moved quickly over the past 24 months, but much of the industry still relies on conventional lab menus and incumbent laboratory networks. AMR Labs SA’s roadmap is centered on two differentiated pillars:
First, a broader and more modern biomarker menu—particularly where mass spectrometry meaningfully improves specificity, interpretability, and clinical relevance compared to routine chemistry.
Second, better sample accessibility through formats that support home collection and global logistics more efficiently, including dried blood spot (DBS) pathways where appropriate. This is central to making advanced testing viable at scale, especially outside traditional clinical settings.
In practical terms, the ambition is to deliver biomarker insights that are both more actionable and harder to replicate—rather than competing solely on packaging, dashboards, or basic panels.
Building a stronger operating backbone
As part of this relaunch, AMR Labs SA is upgrading the end-to-end operating model across:
-
Platform experience: kit registration, tracking, results delivery, and longitudinal follow-up.
-
Logistics and fulfilment: clearer routing, higher predictability, and better support workflows for customers and partners.
- Quality and compliance: standardized processes that can support professional distribution and regulated pathways as the platform expands.
The goal is to make the experience reliable enough for high-expectation consumer users—and robust enough for B2B partners distributing at scale.
CLIA Certificate of Registration secured
A key milestone underpinning this relaunch is regulatory-grade operational readiness for the US market: AMR Labs SA has secured a CLIA Certificate of Registration (ID 99D2335130) for its laboratory operations.
CLIA (Clinical Laboratory Improvement Amendments) is the US framework that sets quality and oversight requirements for laboratories performing testing for health-related purposes. In practical terms, this certificate formalizes that our lab is operating within the CLIA system and can proceed on the pathway required to deliver compliant testing workflows for the US market.
For partners, this matters because it signals a higher bar on execution: validated processes, structured documentation, quality controls, and audit readiness—built into the operating model from day one. For customers, it translates into more reliable and reproducible results, delivered through a platform designed to scale responsibly.
This is not the end state—it is the foundation. And it is a meaningful one: it allows us to industrialize Biostarks’ at-home testing ambition with US-grade compliance as a baseline, not an afterthought.
The next layer: AI-enabled interpretation that stays grounded
We are investing in an AI insight layer designed to make biomarker results easier to understand without drifting into overconfident “diagnostic” language or generic wellness advice.
Our focus is pragmatic: interpret results in context, identify meaningful patterns across biomarkers, and translate that into prioritized actions and tracking recommendations—while remaining conservative on medical claims and transparent about uncertainty.
As we expand the biomarker menu, the AI layer becomes more valuable, not less. Novel biomarkers are only useful if they can be explained clearly, tracked over time, and tied to interventions that people can actually implement.
A note from the CEO
Biostarks earned attention because the vision was directionally correct. The opportunity now is to execute it properly—raising the bar on lab quality, deepening the biomarker menu, and building an experience that partners can rely on. This acquisition is the beginning of that rebuild, and we are moving fast.
Romain Dorange-Pattoret, CEO, AMR Labs SA
What to expect next
In the coming weeks, we will share additional updates across product availability, panel expansion, partner distribution, and platform enhancements. We will also provide clearer documentation on operational policies, customer support pathways, and the upgraded testing roadmap.
If you are a partner interested in distribution, corporate wellness, practitioner channels, or co-branded programs, AMR Labs SA is actively opening conversations.
For general inquiries, partnerships, or press, please contact: hello@biostarks.com
Further updates will be published on this blog.
